Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.38 |
| ▸ | RELA | Q04206 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852586 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL968866 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL2953173 | 0.83 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL4417335 | 0.83 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL5613785 | 0.83 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL3449840 | 0.81 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL5634238 | 0.81 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL13734264 | 0.76 | NLRP3 (0.39) | NFKB1NFKB2RELA | |
| SCHEMBL15007568 | 0.75 | — | — | |
| SCHEMBL8577970 | 0.73 | NFKB1 (0.46) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0137539-B1 | N-SUBSTITUTED TETRAHYDROTHIAZINES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS PESTICIDES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-05-04 | — | — | EP | claimed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | claimed |
| US-4009196-A | HYPOTENSIVE AGENTS, BRONCHODILATORS, PROSTAGLANDIN ANALOGS | TEIJIN LIMITED (JA) | 1977-02-22 | — | — | US | claimed |
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2024-08-06 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | UNIV HONG KONG CHINESE (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-3663305-B1 | METHOD FOR INTRODUCING SUBSTITUENTS INTO ALPHA,BETA-UNSATURATED KETONE AND PROSTAGLANDIN COMPOUND SYNTHESIS METHOD UTILIZING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-110959009-B | Method for introducing substituent to alpha, beta-unsaturated ketone and method for synthesizing prostanoid using the same | 国立研究开发法人国立长寿医疗研究中心 | 2023-02-28 | — | — | CN | disclosed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| EP-0079733-A2 | Process for prostaglandin E1, production and novel delta 7-prostaglandines E and 7-hydroxyprostaglandins E | TEIJIN LIMITED (JP) | 1983-05-25 | — | — | EP | disclosed |
| EP-0051284-A1 | Novel thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceuticals containing these compounds | TEIJIN LIMITED (JP) | 1982-05-12 | — | — | EP | disclosed |
| US-4315032-A | ANTITHROMBOGENIC AGENTS, ANTIULCER AGENTS | TEITIN LIMITED (JP) | 1982-02-09 | — | — | US | disclosed |
| EP-0038613-A1 | Novel prostaglandins E1 and anti-thrombotic compositions containing them | TEIJIN LIMITED (JP) | 1981-10-28 | — | — | EP | disclosed |
| EP-0019475-A2 | Process for preparing adjacently disubstituted ketones, novel prostaglandins E1 and anti-thrombotic compositions containing them | TEIJIN LIMITED (JP) | 1980-11-26 | — | — | EP | disclosed |
| US-4180672-A | 2-Organothio-2-cyclopentenones, organothio-cyclopentanes derived therefrom | TEIJIN LIMITED (JP) | 1979-12-25 | — | — | US | disclosed |
| US-4139717-A | 1,3-Dicarbonyl compounds | TEIJIN LIMITED (JP) | 1979-02-13 | — | — | US | disclosed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | disclosed |
| US-4009196-A | HYPOTENSIVE AGENTS, BRONCHODILATORS, PROSTAGLANDIN ANALOGS | TEIJIN LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | NFKB1 3644/4885NFKB2 4063/4885RELA 3956/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | NFKB1 3644/4885NFKB2 4063/4885RELA 3956/4885 |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | PNP, SLC29A1, SLC29A2 | NFKB1 2790/4885NFKB2 3087/4885RELA 2172/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NFKB1 3644/4885NFKB2 4063/4885RELA 3956/4885 |
| US-12053451-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | NFKB1 1570/4885NFKB2 1372/4885RELA 1748/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NFKB1 3644/4885NFKB2 4063/4885RELA 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.